Abstract
Purinergic signalling is involved in the control of vascular tone and remodelling. Endothelial cells release purines and pyrimidines in response to changes in blood flow (evoking shear stress) and hypoxia. They then act on P2Y, P2X and P1 receptors on endothelial cells leading to release of EDRF mediated by nitric oxide and prostaglandins and EDHF, resulting in vasodilatation. The therapeutic potential of purinergic compounds for the treatment of vascular diseases, including hypertension, ischaemia, atherosclerosis, migraine and coronary artery and diabetic vascular disease as well as vasospasm is discussed.
Keywords: Purinoceptors, nitric oxide, ATP, angiogenesis, atherosclerosis, hypertension, ischaemia, migraine.
Current Vascular Pharmacology
Title:Purinergic Signalling and Endothelium
Volume: 14 Issue: 2
Author(s): Geoffrey Burnstock
Affiliation:
Keywords: Purinoceptors, nitric oxide, ATP, angiogenesis, atherosclerosis, hypertension, ischaemia, migraine.
Abstract: Purinergic signalling is involved in the control of vascular tone and remodelling. Endothelial cells release purines and pyrimidines in response to changes in blood flow (evoking shear stress) and hypoxia. They then act on P2Y, P2X and P1 receptors on endothelial cells leading to release of EDRF mediated by nitric oxide and prostaglandins and EDHF, resulting in vasodilatation. The therapeutic potential of purinergic compounds for the treatment of vascular diseases, including hypertension, ischaemia, atherosclerosis, migraine and coronary artery and diabetic vascular disease as well as vasospasm is discussed.
Export Options
About this article
Cite this article as:
Burnstock Geoffrey, Purinergic Signalling and Endothelium, Current Vascular Pharmacology 2016; 14 (2) . https://dx.doi.org/10.2174/1570161114666151202204948
DOI https://dx.doi.org/10.2174/1570161114666151202204948 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D Deficiency: Universal Risk Factor for Multifactorial Diseases?
Current Drug Targets Simultaneous Monitoring of Febuxostat and Uric Acid in Human Serum Samples Using the Direct Square-Wave Voltammetric Method
Current Analytical Chemistry Synthesis and Biological Evaluation of Some [1,2,4]Triazolo[3,4-b][1,3,4]Thiadiazoles and [1,2,4]Triazolo[3,4-b][1,3,4]Thiadiazines
Letters in Drug Design & Discovery New Drugs for Epidural Analgesia
Current Drug Targets Morbidity and Mortality Associated with Pharmacotherapy. Evolution and Current Concept of Drug-Related Problems
Current Pharmaceutical Design The Renin-Angiotensin System: Emerging Concepts
Current Hypertension Reviews Evaluation and Management of Atrial Fibrillation
Cardiovascular & Hematological Disorders-Drug Targets Editorial [Hot Topic: The Endothelin System: Vascular Targets for Therapy in Disease (Guest Editor: Michael R. Dashwood)]
Current Vascular Pharmacology Editorial [Hot topic: Updates on Therapeutic Approaches to Inflammatory Skin Diseases: From Molecular Targets to Drug Development. Part II (Guest Editors: L. Korkina & S. Pastore)]
Current Drug Metabolism MicroRNA-136 Promotes Vascular Muscle Cell Proliferation Through the ERK1/2 Pathway by Targeting PPP2R2A in Atherosclerosis
Current Vascular Pharmacology Oxidative stress and myocarditis
Current Pharmaceutical Design Anti-Inflammatory and Anti-Allergy Drugs in Rhinosinusitis
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Vascular Remodelling in Well-controlled Hypertensive Patients: The Challenge of Residual Risk Management
Current Pharmaceutical Design Inflammation and Chronic Heart Failure: From Biomarkers to Novel Anti-inflammatory Therapeutic Strategies
Medicinal Chemistry Flow Volumes of Internal Jugular Veins are Significantly Reduced in Patients with Cerebral Venous Sinus Thrombosis
Current Neurovascular Research The Lung Disease of Rheumatoid Arthritis
Current Respiratory Medicine Reviews Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Is there a Role for Bevacizumab in Non-Glial Tumors?
Current Drug Targets Metabolic Syndrome, its Pathophysiology and the Role of Melatonin
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Nerve Growth Factor: A Focus on Neuroscience and Therapy
Current Neuropharmacology